• Activity INFORMATION

  Overview

  Is naloxone everywhere and nowhere at the same time? Recent FDA approvals have enabled the distribution of naloxone products via the over-the-counter (OTC) supply chain, while still being available in multiple formulations via prescription. Is enabling OTC sales of naloxone the panacea of “ending the opioid crisis” as we know it? Let’s slow down a bit and mitigate the hysteria and confusion beyond the relatively straight-forward administration of naloxone products. This program will review the signs and symptoms of opioid overdose, the FDA-approved OTC and prescription opioid overdose respiratory depression reversal products, the opioid overdose respiratory depression reversal medication administration guidelines, and general important pharmacological characteristics of the mu-opioid antagonist naloxone. Naloxone saves lives by reversing opioid overdose respiratory depression, let’s respect its pharmacology, address its realities, and go save some lives!
  

  Handouts

  • Slide Document :   23238H08_2pp.pdf Download

  • Slide Document :   23238H08_6pp.pdf Download

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  Recognize opioid overdose symptoms

  Identify clinically important pharmacological characteristics of naloxone

  Recall FDA-approved over-the-counter (OTC) and prescription (Rx) opioid overdose respiratory depression reversal naloxone products and administration guidelines

  Pharmacy Technician

  Identify clinically important pharmacological characteristics of naloxone

  Recognize opioid overdose symptoms

  Recall FDA-approved over-the-counter (OTC) and prescription (Rx) opioid overdose respiratory depression reversal naloxone products and administration guidelines

  Nurse

  Recognize opioid overdose symptoms

  Recall FDA-approved over-the-counter (OTC) and prescription (Rx) opioid overdose respiratory depression reversal naloxone products and administration guidelines

  Identify clinically important pharmacological characteristics of naloxone

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-1173334

  Universal Activity Number

  Pharmacist 0798-0000-23-238-H08-P
  Pharmacy Technician 0798-0000-23-238-H08-T
  Nurse 0798-0000-23-238-H08-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Mark  Garofoli, PharmD, MBA, BCGP, CPE, CTTS Assistant Professor, West Virginia University School of Pharmacy

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).